Summary

The global Daptomycin API market is projected to grow from US$ 67.01 million in 2025 to US$ 112 million by 2032, at a CAGR of 7.4% (2026-2032), driven by critical product segments and diverse end‑use applications. In 2025, global Daptomycin API capacity 5 Tons, sales reached approximately 4.5 Tons, with an average market price of around 14,890 USD/Kg, industrial gross margin 28%. Daptomycin is a cyclic lipopeptide antibacterial positioned in the high-value, low-tonnage segment of the anti-infective API industry, where process control and regulatory continuity matter materially more than nominal manufacturing scale. The molecule has the formula C₇₂H₁₀₁N₁₇O₂₆ and a molecular weight of approximately 1,620.7 Da; its antibacterial activity is driven by calcium-dependent insertion into Gram-positive bacterial membranes, rapid membrane depolarization, and subsequent arrest of DNA, RNA and protein synthesis. The relevant industrial market is pharmaceutical-grade API or drug substance rather than finished 350 mg or 500 mg injectable vials, laboratory reagents, analytical standards or fermentation intermediates. Commercial API programs are typically positioned in the high-98% to ≥99% HPLC purity range, but pharmaceutical suitability is governed by a broader specification covering individual and total related substances, residual solvents, water, microbiological attributes and stability. Storage is process- and registration-specific: validated commercial supply chains may use refrigerated conditions of 2–8°C or frozen storage around −20°C, while registered products can carry shelf lives of approximately three years. These requirements make stability data, cold-chain control and manufacturing-change discipline integral to commercial qualification rather than secondary logistics considerations. The manufacturing platform is built around controlled microbial fermentation followed by a purification train that is substantially more demanding than conventional small-molecule API synthesis. Industrial production uses Streptomyces roseosporus fermentation with controlled fatty-acid precursor feeding, followed by broth clarification, adsorption, ion-exchange chromatography, hydrophobic-interaction or reversed-phase chromatography, membrane concentration and final crystallization or lyophilization. Cost competitiveness is determined by strain productivity, precursor-feed control, impurity formation, chromatographic selectivity, resin productivity and downstream recovery rather than fermenter volume alone. Structurally related lipopeptide congeners are difficult to separate, and incremental purity improvement can require disproportionate resin, solvent and product-loss penalties. As a result, process development is moving upstream: preventing unwanted analogues during fermentation is economically preferable to removing them through additional chromatography. The supply chain therefore extends beyond conventional fermentation nutrients to specialized resins, membrane systems, high-purity solvents, analytical instrumentation and validated clean utilities. Downstream customers are sterile-injectable manufacturers, and supplier onboarding commonly involves analytical comparability, stability packages, quality-system audits, regulatory-file access, validation batches and formal change-control arrangements. Demand is anchored in serious Gram-positive infections rather than broad outpatient antibiotic use, which gives the product a resilient but clinically bounded commercial profile. Approved applications include complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis. Typical adult regimens include 4 mg/kg every 24 hours for cSSSI and 6 mg/kg every 24 hours for S. aureus bacteremia, with extended dosing intervals in severe renal impairment. Daptomycin is not indicated for pneumonia, which materially limits the addressable clinical setting relative to several broad-spectrum agents. The United States remains one of the most established commercial markets because of early adoption and a mature generic injectable ecosystem, while Europe combines stable institutional demand with stringent GMP and dossier requirements. Japan and other regulated Asian markets place strong emphasis on supplier consistency and change control. China is distinct because it combines a large fermentation-API manufacturing base with an expanding domestic generic-injectable market; inclusion of daptomycin injection in national volume-based procurement has increased the importance of API cost efficiency, forecast reliability and diversified qualified sourcing for finished-dose manufacturers. Competition is led by a relatively small group of technically experienced anti-infective manufacturers in Europe and China, with regulatory reach and impurity-control capability serving as the primary differentiators. Xellia Pharmaceuticals manufactures the API in Budapest and supports U.S. and European regulatory dossiers, while ACS Dobfar supplies Daptomycin Drug Substance from its Italian anti-infective platform. In China, representative producers include Livzon Group Fuzhou Fuxing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Medicine and the Huadong Medicine manufacturing system, alongside specialized suppliers such as Chongqing Daxin Pharmaceutical and Sichuan Novals Pharmaceuticals. Recent competitive activity is increasingly vertical rather than purely capacity-driven. Zhejiang Medicine’s controlled subsidiary Changhai Pharmaceutical obtained domestic approval for daptomycin API in 2023 after regulatory and FDA-related site work, and Zhejiang Medicine subsequently received Chinese approval for a 0.5 g daptomycin injectable in August 2024 after cumulative R&D spending of approximately RMB15.2 million on the formulation program. The move extends the company from drug-substance production into finished-dose commercialization. In parallel, Huadong Medicine’s manufacturing platform filed a 2024 patent covering high-purity daptomycin crystal preparation, emphasizing shorter purification, lower solvent consumption and industrial scalability, illustrating how process intensification is becoming a competitive asset. Growth will be shaped by generic penetration, higher-purity API migration, second-source qualification and supply-chain resilience rather than unrestricted expansion in antibiotic consumption. On the demand side, persistent treatment needs for resistant Gram-positive infections support a stable clinical base, while antimicrobial stewardship and therapeutic alternatives such as vancomycin, linezolid and newer anti-MRSA agents cap volume elasticity. On the technology side, strain improvement, precision precursor feeding, online fermentation monitoring, selective chromatography, resin reuse and membrane-based concentration offer the clearest path to lower unit cost without compromising quality. Supply strategies are also changing: flexible multiproduct fermentation sites combined with dedicated critical purification steps and geographically diversified regulatory files are more attractive than large standalone daptomycin lines. Competitive advantage will increasingly reside with manufacturers able to support China, the United States, Europe and selected Asian markets from stable processes and harmonized dossiers. For Chinese suppliers, the most defensible opportunities are higher-purity grades, regulated-market second-source programs, domestic generic-injectable expansion and selective API-to-FDF integration; the principal constraints remain the narrow clinical scope, long customer-validation cycles, environmental-compliance costs, structural spare capacity and trade-policy uncertainty. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Daptomycin API market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Purity and by Finished-dose, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed. Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company Olon Xellia Pharmaceuticals Livzon Group Fuzhou Fuxing Pharmaceutical Huadong Medicine Zhejiang Hisun Pharmaceutical Zhejiang Medicine Chongqing Daxin Pharmaceutical Lunan New Times Biotechnology Sichuan Novals Pharmaceuticals Fujian Comhony Biotechnology Suzhou Biosynergy Pharmaceutical North China Pharmaceutical Segment by Purity ≥99% <99% Segment by Manufacturing Technology Conventional Fed-batch High-titer Optimized Fermentation Segment by Customer Business Model Independent Generic Injectable Manufacturers Vertically Integrated Pharmaceutical Groups Others Segment by Finished-dose 500 mg/vial 350 mg/vial Sales by Region North America U.S. Canada Mexico Asia-Pacific China Japan South Korea India China Taiwan Southeast Asia (Indonesia, Vietnam, Thailand) Europe Germany France U.K. Italy Russia Central and South America Brazil Argentina Rest of Central and South America Middle East, Africa Turkey Egypt GCC Countries South Africa Chapter Outline Chapter 1: Defines the Daptomycin API study scope, segments the market by Purity and by Finished-dose, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Finished-dose, identifies emerging use cases, and profiles leading customers by region and by Finished-dose Chapter 6: North America: breaks down sales and revenue by Finished-dose and country, profiles key manufacturers and assesses growth drivers and barriers Chapter 7: Europe: analyses regional sales, revenue and market by Finished-dose and manufacturers, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies sales and revenue by Finished-dose, and region/country, profiles top manufacturers, and uncovers high potential expansion areas Chapter 9: Central & South America: measures sales and revenue by Finished-dose, and country, profiles top manufacturers, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates sales and revenue by Finished-dose, and country, profiles key manufacturers, and outlines investment prospects and market hurdles Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Finished-dose, by sales region SWOT analysis, and recent strategic developments Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Daptomycin API: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Purity
1.2.1 Global Daptomycin API Market Size by Purity, 2021 vs 2025 vs 2032
1.2.2 ≥99%
1.2.3 <99%
1.3 Market Segmentation by Manufacturing Technology
1.3.1 Global Daptomycin API Market Size by Manufacturing Technology, 2021 vs 2025 vs 2032
1.3.2 Conventional Fed-batch
1.3.3 High-titer Optimized Fermentation
1.4 Market Segmentation by Customer Business Model
1.4.1 Global Daptomycin API Market Size by Customer Business Model, 2021 vs 2025 vs 2032
1.4.2 Independent Generic Injectable Manufacturers
1.4.3 Vertically Integrated Pharmaceutical Groups
1.4.4 Others
1.5 Market Segmentation by Finished-dose
1.5.1 Global Daptomycin API Market Size by Finished-dose, 2021 vs 2025 vs 2032
1.5.2 500 mg/vial
1.5.3 350 mg/vial
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Daptomycin API Revenue Estimates and Forecasts (2021-2032)
2.2 Global Daptomycin API Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Daptomycin API Sales Estimates and Forecasts (2021-2032)
2.4 Global Daptomycin API Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Daptomycin API Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Daptomycin API Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 ≥99%: Market Share by Key Manufacturers
3.5.2 <99%: Market Share by Key Manufacturers
3.6 Global Daptomycin API Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Daptomycin API Sales Performance by Purity
4.1.1 Global Daptomycin API Sales Volume by Purity (2021-2032)
4.1.2 Global Daptomycin API Revenue by Purity (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Purity (2021-2032)
4.2 Global Daptomycin API Sales Performance by Manufacturing Technology
4.2.1 Global Daptomycin API Sales Volume by Manufacturing Technology (2021-2032)
4.2.2 Global Daptomycin API Revenue by Manufacturing Technology (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Manufacturing Technology (2021-2032)
4.3 Global Daptomycin API Sales Performance by Customer Business Model
4.3.1 Global Daptomycin API Sales Volume by Customer Business Model (2021-2032)
4.3.2 Global Daptomycin API Revenue by Customer Business Model (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Customer Business Model (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Daptomycin API Sales by Finished-dose
5.1.1 Global Historical and Forecasted Sales by Finished-dose (2021-2032)
5.1.2 Global Sales Market Share by Finished-dose (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Daptomycin API Revenue by Finished-dose
5.2.1 Global Historical and Forecasted Revenue by Finished-dose (2021-2032)
5.2.2 Revenue-Based Market Share by Finished-dose (2021-2032)
5.3 Global Pricing Dynamics by Finished-dose (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Finished-dose

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Daptomycin API Sales and Revenue by Finished-dose (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Daptomycin API Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Daptomycin API Sales and Revenue by Finished-dose (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Daptomycin API Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Daptomycin API Sales and Revenue by Finished-dose (2021-2032)
8.4 Asia-Pacific Daptomycin API Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Daptomycin API Sales and Revenue by Finished-dose (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Daptomycin API Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Daptomycin API Sales and Revenue by Finished-dose (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Daptomycin API Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Olon
11.1.1 Olon Corporation Information
11.1.2 Olon Business Overview
11.1.3 Olon Daptomycin API Product Models, Descriptions and Specifications
11.1.4 Olon Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Olon Daptomycin API Sales by Product in 2025
11.1.6 Olon Daptomycin API Sales by Finished-dose in 2025
11.1.7 Olon Daptomycin API Sales by Geographic Area in 2025
11.1.8 Olon Daptomycin API SWOT Analysis
11.1.9 Olon Recent Developments
11.2 Xellia Pharmaceuticals
11.2.1 Xellia Pharmaceuticals Corporation Information
11.2.2 Xellia Pharmaceuticals Business Overview
11.2.3 Xellia Pharmaceuticals Daptomycin API Product Models, Descriptions and Specifications
11.2.4 Xellia Pharmaceuticals Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Xellia Pharmaceuticals Daptomycin API Sales by Product in 2025
11.2.6 Xellia Pharmaceuticals Daptomycin API Sales by Finished-dose in 2025
11.2.7 Xellia Pharmaceuticals Daptomycin API Sales by Geographic Area in 2025
11.2.8 Xellia Pharmaceuticals Daptomycin API SWOT Analysis
11.2.9 Xellia Pharmaceuticals Recent Developments
11.3 Livzon Group Fuzhou Fuxing Pharmaceutical
11.3.1 Livzon Group Fuzhou Fuxing Pharmaceutical Corporation Information
11.3.2 Livzon Group Fuzhou Fuxing Pharmaceutical Business Overview
11.3.3 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Product Models, Descriptions and Specifications
11.3.4 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Sales by Product in 2025
11.3.6 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Sales by Finished-dose in 2025
11.3.7 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Sales by Geographic Area in 2025
11.3.8 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API SWOT Analysis
11.3.9 Livzon Group Fuzhou Fuxing Pharmaceutical Recent Developments
11.4 Huadong Medicine
11.4.1 Huadong Medicine Corporation Information
11.4.2 Huadong Medicine Business Overview
11.4.3 Huadong Medicine Daptomycin API Product Models, Descriptions and Specifications
11.4.4 Huadong Medicine Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Huadong Medicine Daptomycin API Sales by Product in 2025
11.4.6 Huadong Medicine Daptomycin API Sales by Finished-dose in 2025
11.4.7 Huadong Medicine Daptomycin API Sales by Geographic Area in 2025
11.4.8 Huadong Medicine Daptomycin API SWOT Analysis
11.4.9 Huadong Medicine Recent Developments
11.5 Zhejiang Hisun Pharmaceutical
11.5.1 Zhejiang Hisun Pharmaceutical Corporation Information
11.5.2 Zhejiang Hisun Pharmaceutical Business Overview
11.5.3 Zhejiang Hisun Pharmaceutical Daptomycin API Product Models, Descriptions and Specifications
11.5.4 Zhejiang Hisun Pharmaceutical Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Zhejiang Hisun Pharmaceutical Daptomycin API Sales by Product in 2025
11.5.6 Zhejiang Hisun Pharmaceutical Daptomycin API Sales by Finished-dose in 2025
11.5.7 Zhejiang Hisun Pharmaceutical Daptomycin API Sales by Geographic Area in 2025
11.5.8 Zhejiang Hisun Pharmaceutical Daptomycin API SWOT Analysis
11.5.9 Zhejiang Hisun Pharmaceutical Recent Developments
11.6 Zhejiang Medicine
11.6.1 Zhejiang Medicine Corporation Information
11.6.2 Zhejiang Medicine Business Overview
11.6.3 Zhejiang Medicine Daptomycin API Product Models, Descriptions and Specifications
11.6.4 Zhejiang Medicine Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Zhejiang Medicine Recent Developments
11.7 Chongqing Daxin Pharmaceutical
11.7.1 Chongqing Daxin Pharmaceutical Corporation Information
11.7.2 Chongqing Daxin Pharmaceutical Business Overview
11.7.3 Chongqing Daxin Pharmaceutical Daptomycin API Product Models, Descriptions and Specifications
11.7.4 Chongqing Daxin Pharmaceutical Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Chongqing Daxin Pharmaceutical Recent Developments
11.8 Lunan New Times Biotechnology
11.8.1 Lunan New Times Biotechnology Corporation Information
11.8.2 Lunan New Times Biotechnology Business Overview
11.8.3 Lunan New Times Biotechnology Daptomycin API Product Models, Descriptions and Specifications
11.8.4 Lunan New Times Biotechnology Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Lunan New Times Biotechnology Recent Developments
11.9 Sichuan Novals Pharmaceuticals
11.9.1 Sichuan Novals Pharmaceuticals Corporation Information
11.9.2 Sichuan Novals Pharmaceuticals Business Overview
11.9.3 Sichuan Novals Pharmaceuticals Daptomycin API Product Models, Descriptions and Specifications
11.9.4 Sichuan Novals Pharmaceuticals Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Sichuan Novals Pharmaceuticals Recent Developments
11.10 Fujian Comhony Biotechnology
11.10.1 Fujian Comhony Biotechnology Corporation Information
11.10.2 Fujian Comhony Biotechnology Business Overview
11.10.3 Fujian Comhony Biotechnology Daptomycin API Product Models, Descriptions and Specifications
11.10.4 Fujian Comhony Biotechnology Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Fujian Comhony Biotechnology Recent Developments
11.11 Suzhou Biosynergy Pharmaceutical
11.11.1 Suzhou Biosynergy Pharmaceutical Corporation Information
11.11.2 Suzhou Biosynergy Pharmaceutical Business Overview
11.11.3 Suzhou Biosynergy Pharmaceutical Daptomycin API Product Models, Descriptions and Specifications
11.11.4 Suzhou Biosynergy Pharmaceutical Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Suzhou Biosynergy Pharmaceutical Recent Developments
11.12 North China Pharmaceutical
11.12.1 North China Pharmaceutical Corporation Information
11.12.2 North China Pharmaceutical Business Overview
11.12.3 North China Pharmaceutical Daptomycin API Product Models, Descriptions and Specifications
11.12.4 North China Pharmaceutical Daptomycin API Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 North China Pharmaceutical Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Daptomycin API Industry Chain
12.2 Daptomycin API Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Daptomycin API Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Daptomycin API Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Daptomycin API Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Daptomycin API Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Daptomycin API Market Size Growth Rate by Purity, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Daptomycin API Market Size Growth Rate by Manufacturing Technology, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Daptomycin API Market Size Growth Rate by Customer Business Model, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Daptomycin API Market Size Growth Rate by Finished-dose, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Daptomycin API Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Daptomycin API Revenue by Region (US$ Million), 2021-2026
Table 7. Global Daptomycin API Revenue by Region (US$ Million), 2027-2032
Table 8. Global Daptomycin API Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (kg)
Table 9. Global Daptomycin API Sales by Region (kg), 2021-2026
Table 10. Global Daptomycin API Sales by Region (kg), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Daptomycin API Sales by Manufacturers (kg), 2021-2026
Table 13. Global Daptomycin API Sales Share by Manufacturers (2021-2026)
Table 14. Global Daptomycin API Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Daptomycin API Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Daptomycin API Revenue, 2025
Table 18. Global Daptomycin API Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Daptomycin API Average Selling Price (ASP) by Manufacturers (US$/kg), 2021-2026
Table 20. Key Manufacturers Daptomycin API Manufacturing Base and Headquarters
Table 21. Global Daptomycin API Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Daptomycin API Sales Volume by Purity (kg), 2021-2026
Table 25. Global Daptomycin API Sales Volume by Purity (kg), 2027-2032
Table 26. Global Daptomycin API Revenue by Purity (US$ Million), 2021-2026
Table 27. Global Daptomycin API Revenue by Purity (US$ Million), 2027-2032
Table 28. Global Daptomycin API Sales Volume by Manufacturing Technology (kg), 2021-2026
Table 29. Global Daptomycin API Sales Volume by Manufacturing Technology (kg), 2027-2032
Table 30. Global Daptomycin API Revenue by Manufacturing Technology (US$ Million), 2021-2026
Table 31. Global Daptomycin API Revenue by Manufacturing Technology (US$ Million), 2027-2032
Table 32. Global Daptomycin API Sales Volume by Customer Business Model (kg), 2021-2026
Table 33. Global Daptomycin API Sales Volume by Customer Business Model (kg), 2027-2032
Table 34. Global Daptomycin API Revenue by Customer Business Model (US$ Million), 2021-2026
Table 35. Global Daptomycin API Revenue by Customer Business Model (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Daptomycin API Sales by Finished-dose (kg), 2021-2026
Table 38. Global Daptomycin API Sales by Finished-dose (kg), 2027-2032
Table 39. Daptomycin API High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Daptomycin API Revenue by Finished-dose (US$ Million), 2021-2026
Table 41. Global Daptomycin API Revenue by Finished-dose (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Finished-dose
Table 44. North America Daptomycin API Growth Accelerators and Market Barriers
Table 45. North America Daptomycin API Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Daptomycin API Sales (kg) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Daptomycin API Growth Accelerators and Market Barriers
Table 48. Europe Daptomycin API Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Daptomycin API Sales (kg) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Daptomycin API Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Daptomycin API Sales (kg) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Daptomycin API Growth Accelerators and Market Barriers
Table 53. Southeast Asia Daptomycin API Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Daptomycin API Investment Opportunities and Key Challenges
Table 55. Central and South America Daptomycin API Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Daptomycin API Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Daptomycin API Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Olon Corporation Information
Table 59. Olon Description and Major Businesses
Table 60. Olon Product Models, Descriptions and Specifications
Table 61. Olon Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 62. Olon Sales Value Proportion by Product in 2025
Table 63. Olon Sales Value Proportion by Finished-dose in 2025
Table 64. Olon Sales Value Proportion by Geographic Area in 2025
Table 65. Olon Daptomycin API SWOT Analysis
Table 66. Olon Recent Developments
Table 67. Xellia Pharmaceuticals Corporation Information
Table 68. Xellia Pharmaceuticals Description and Major Businesses
Table 69. Xellia Pharmaceuticals Product Models, Descriptions and Specifications
Table 70. Xellia Pharmaceuticals Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 71. Xellia Pharmaceuticals Sales Value Proportion by Product in 2025
Table 72. Xellia Pharmaceuticals Sales Value Proportion by Finished-dose in 2025
Table 73. Xellia Pharmaceuticals Sales Value Proportion by Geographic Area in 2025
Table 74. Xellia Pharmaceuticals Daptomycin API SWOT Analysis
Table 75. Xellia Pharmaceuticals Recent Developments
Table 76. Livzon Group Fuzhou Fuxing Pharmaceutical Corporation Information
Table 77. Livzon Group Fuzhou Fuxing Pharmaceutical Description and Major Businesses
Table 78. Livzon Group Fuzhou Fuxing Pharmaceutical Product Models, Descriptions and Specifications
Table 79. Livzon Group Fuzhou Fuxing Pharmaceutical Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 80. Livzon Group Fuzhou Fuxing Pharmaceutical Sales Value Proportion by Product in 2025
Table 81. Livzon Group Fuzhou Fuxing Pharmaceutical Sales Value Proportion by Finished-dose in 2025
Table 82. Livzon Group Fuzhou Fuxing Pharmaceutical Sales Value Proportion by Geographic Area in 2025
Table 83. Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API SWOT Analysis
Table 84. Livzon Group Fuzhou Fuxing Pharmaceutical Recent Developments
Table 85. Huadong Medicine Corporation Information
Table 86. Huadong Medicine Description and Major Businesses
Table 87. Huadong Medicine Product Models, Descriptions and Specifications
Table 88. Huadong Medicine Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 89. Huadong Medicine Sales Value Proportion by Product in 2025
Table 90. Huadong Medicine Sales Value Proportion by Finished-dose in 2025
Table 91. Huadong Medicine Sales Value Proportion by Geographic Area in 2025
Table 92. Huadong Medicine Daptomycin API SWOT Analysis
Table 93. Huadong Medicine Recent Developments
Table 94. Zhejiang Hisun Pharmaceutical Corporation Information
Table 95. Zhejiang Hisun Pharmaceutical Description and Major Businesses
Table 96. Zhejiang Hisun Pharmaceutical Product Models, Descriptions and Specifications
Table 97. Zhejiang Hisun Pharmaceutical Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 98. Zhejiang Hisun Pharmaceutical Sales Value Proportion by Product in 2025
Table 99. Zhejiang Hisun Pharmaceutical Sales Value Proportion by Finished-dose in 2025
Table 100. Zhejiang Hisun Pharmaceutical Sales Value Proportion by Geographic Area in 2025
Table 101. Zhejiang Hisun Pharmaceutical Daptomycin API SWOT Analysis
Table 102. Zhejiang Hisun Pharmaceutical Recent Developments
Table 103. Zhejiang Medicine Corporation Information
Table 104. Zhejiang Medicine Description and Major Businesses
Table 105. Zhejiang Medicine Product Models, Descriptions and Specifications
Table 106. Zhejiang Medicine Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 107. Zhejiang Medicine Recent Developments
Table 108. Chongqing Daxin Pharmaceutical Corporation Information
Table 109. Chongqing Daxin Pharmaceutical Description and Major Businesses
Table 110. Chongqing Daxin Pharmaceutical Product Models, Descriptions and Specifications
Table 111. Chongqing Daxin Pharmaceutical Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 112. Chongqing Daxin Pharmaceutical Recent Developments
Table 113. Lunan New Times Biotechnology Corporation Information
Table 114. Lunan New Times Biotechnology Description and Major Businesses
Table 115. Lunan New Times Biotechnology Product Models, Descriptions and Specifications
Table 116. Lunan New Times Biotechnology Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 117. Lunan New Times Biotechnology Recent Developments
Table 118. Sichuan Novals Pharmaceuticals Corporation Information
Table 119. Sichuan Novals Pharmaceuticals Description and Major Businesses
Table 120. Sichuan Novals Pharmaceuticals Product Models, Descriptions and Specifications
Table 121. Sichuan Novals Pharmaceuticals Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 122. Sichuan Novals Pharmaceuticals Recent Developments
Table 123. Fujian Comhony Biotechnology Corporation Information
Table 124. Fujian Comhony Biotechnology Description and Major Businesses
Table 125. Fujian Comhony Biotechnology Product Models, Descriptions and Specifications
Table 126. Fujian Comhony Biotechnology Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 127. Fujian Comhony Biotechnology Recent Developments
Table 128. Suzhou Biosynergy Pharmaceutical Corporation Information
Table 129. Suzhou Biosynergy Pharmaceutical Description and Major Businesses
Table 130. Suzhou Biosynergy Pharmaceutical Product Models, Descriptions and Specifications
Table 131. Suzhou Biosynergy Pharmaceutical Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 132. Suzhou Biosynergy Pharmaceutical Recent Developments
Table 133. North China Pharmaceutical Corporation Information
Table 134. North China Pharmaceutical Description and Major Businesses
Table 135. North China Pharmaceutical Product Models, Descriptions and Specifications
Table 136. North China Pharmaceutical Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 137. North China Pharmaceutical Recent Developments
Table 138. Key Raw Materials Distribution
Table 139. Raw Materials Key Suppliers
Table 140. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 141. Milestones in Production Technology Evolution
Table 142. Distributors List
Table 143. Market Trends and Market Evolution
Table 144. Market Drivers and Opportunities
Table 145. Market Challenges, Risks, and Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources

List of Figures
Figure 1. Daptomycin API Product Picture
Figure 2. Global Daptomycin API Market Size Growth Rate by Purity, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. ≥99% Product Picture
Figure 4. <99% Product Picture
Figure 5. Global Daptomycin API Market Size Growth Rate by Manufacturing Technology, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Conventional Fed-batch Product Picture
Figure 7. High-titer Optimized Fermentation Product Picture
Figure 8. Global Daptomycin API Market Size Growth Rate by Customer Business Model, 2021 vs 2025 vs 2032 (US$ Million)
Figure 9. Independent Generic Injectable Manufacturers Product Picture
Figure 10. Vertically Integrated Pharmaceutical Groups Product Picture
Figure 11. Others Product Picture
Figure 12. Global Daptomycin API Market Size Growth Rate by Finished-dose, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. 500 mg/vial
Figure 14. 350 mg/vial
Figure 15. Daptomycin API Report Years Considered
Figure 16. Global Daptomycin API Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Daptomycin API Revenue (US$ Million), 2021-2032
Figure 18. Global Daptomycin API Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 19. Global Daptomycin API Revenue-Based Market Share by Region (2021-2032)
Figure 20. Global Daptomycin API Sales (kg), 2021-2032
Figure 21. Global Daptomycin API Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (kg)
Figure 22. Global Daptomycin API Sales Market Share by Region (2021-2032)
Figure 23. Top 5 and Top 10 Manufacturers Daptomycin API Sales Volume Market Share in 2025
Figure 24. Global Daptomycin API Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. ≥99% Revenue-Based Market Share by Manufacturer in 2025
Figure 27. <99% Revenue-Based Market Share by Manufacturer in 2025
Figure 28. Global Daptomycin API Sales Volume-Based Market Share by Purity (2021-2032)
Figure 29. Global Daptomycin API Revenue-Based Market Share by Purity (2021-2032)
Figure 30. Global Daptomycin API ASP by Purity (US$/kg), 2021-2032
Figure 31. Global Daptomycin API Sales Volume-Based Market Share by Manufacturing Technology (2021-2032)
Figure 32. Global Daptomycin API Revenue-Based Market Share by Manufacturing Technology (2021-2032)
Figure 33. Global Daptomycin API ASP by Manufacturing Technology (US$/kg), 2021-2032
Figure 34. Global Daptomycin API Sales Volume-Based Market Share by Customer Business Model (2021-2032)
Figure 35. Global Daptomycin API Revenue-Based Market Share by Customer Business Model (2021-2032)
Figure 36. Global Daptomycin API ASP by Customer Business Model (US$/kg), 2021-2032
Figure 37. Global Daptomycin API Sales Market Share by Finished-dose (2021-2032)
Figure 38. Global Daptomycin API Revenue-Based Market Share by Finished-dose (2021-2032)
Figure 39. Global Daptomycin API ASP by Finished-dose (US$/kg), 2021-2032
Figure 40. North America Daptomycin API Sales YoY (kg), 2021-2032
Figure 41. North America Daptomycin API Revenue YoY (US$ Million), 2021-2032
Figure 42. North America Top 5 Manufacturers Daptomycin API Sales Revenue (US$ Million) in 2025
Figure 43. North America Daptomycin API Sales Volume (kg) by Finished-dose (2021-2032)
Figure 44. North America Daptomycin API Sales Revenue (US$ Million) by Finished-dose (2021-2032)
Figure 45. US Daptomycin API Revenue (US$ Million), 2021-2032
Figure 46. Canada Daptomycin API Revenue (US$ Million), 2021-2032
Figure 47. Mexico Daptomycin API Revenue (US$ Million), 2021-2032
Figure 48. Europe Daptomycin API Sales YoY (kg), 2021-2032
Figure 49. Europe Daptomycin API Revenue YoY (US$ Million), 2021-2032
Figure 50. Europe Top 5 Manufacturers Daptomycin API Sales Revenue (US$ Million) in 2025
Figure 51. Europe Daptomycin API Sales Volume (kg) by Finished-dose (2021-2032)
Figure 52. Europe Daptomycin API Sales Revenue (US$ Million) by Finished-dose (2021-2032)
Figure 53. Germany Daptomycin API Revenue (US$ Million), 2021-2032
Figure 54. France Daptomycin API Revenue (US$ Million), 2021-2032
Figure 55. U.K. Daptomycin API Revenue (US$ Million), 2021-2032
Figure 56. Italy Daptomycin API Revenue (US$ Million), 2021-2032
Figure 57. Russia Daptomycin API Revenue (US$ Million), 2021-2032
Figure 58. Asia-Pacific Daptomycin API Sales YoY (kg), 2021-2032
Figure 59. Asia-Pacific Daptomycin API Revenue YoY (US$ Million), 2021-2032
Figure 60. Asia-Pacific Top 8 Manufacturers Daptomycin API Sales Revenue (US$ Million) in 2025
Figure 61. Asia-Pacific Daptomycin API Sales Volume (kg) by Finished-dose (2021-2032)
Figure 62. Asia-Pacific Daptomycin API Sales Revenue (US$ Million) by Finished-dose (2021-2032)
Figure 63. Indonesia Daptomycin API Revenue (US$ Million), 2021-2032
Figure 64. Japan Daptomycin API Revenue (US$ Million), 2021-2032
Figure 65. South Korea Daptomycin API Revenue (US$ Million), 2021-2032
Figure 66. China Taiwan Daptomycin API Revenue (US$ Million), 2021-2032
Figure 67. India Daptomycin API Revenue (US$ Million), 2021-2032
Figure 68. Central and South America Daptomycin API Sales YoY (kg), 2021-2032
Figure 69. Central and South America Daptomycin API Revenue YoY (US$ Million), 2021-2032
Figure 70. Central and South America Top 5 Manufacturers Daptomycin API Sales Revenue (US$ Million) in 2025
Figure 71. Central and South America Daptomycin API Sales Volume (kg) by Finished-dose (2021-2032)
Figure 72. Central and South America Daptomycin API Sales Revenue (US$ Million) by Finished-dose (2021-2032)
Figure 73. Brazil Daptomycin API Revenue (US$ Million), 2021-2032
Figure 74. Argentina Daptomycin API Revenue (US$ Million), 2021-2032
Figure 75. Middle East, and Africa Daptomycin API Sales YoY (kg), 2021-2032
Figure 76. Middle East and Africa Daptomycin API Revenue YoY (US$ Million), 2021-2032
Figure 77. Middle East and Africa Top 5 Manufacturers Daptomycin API Sales Revenue (US$ Million) in 2025
Figure 78. Middle East and Africa Daptomycin API Sales Volume (kg) by Finished-dose (2021-2032)
Figure 79. Middle East and Africa Daptomycin API Sales Revenue (US$ Million) by Finished-dose (2021-2032)
Figure 80. GCC Countries Daptomycin API Revenue (US$ Million), 2021-2032
Figure 81. Turkey Daptomycin API Revenue (US$ Million), 2021-2032
Figure 82. Egypt Daptomycin API Revenue (US$ Million), 2021-2032
Figure 83. South Africa Daptomycin API Revenue (US$ Million), 2021-2032
Figure 84. Daptomycin API Industry Chain Mapping
Figure 85. Regional Daptomycin API Manufacturing Base Distribution (%)
Figure 86. Global Daptomycin API Production Market Share by Region (2021-2032)
Figure 87. Daptomycin API Production Process
Figure 88. Regional Daptomycin API Production Cost Structure
Figure 89. Channels of Distribution (Direct Vs Distribution)
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed